Changes in ER, PR, HER2, and Their Association With Disease Outcome in Invasive Breast Carcinoma (IBC) Patients Post-Neo Adjuvant Chemotherapy (NAC) and Surgery
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Changes in estrogen receptor (ER) and HER2 status after neoadjuvant chemotherapy (NAC) in invasive breast carcinoma (IBC) with residual tumors correlate with better disease-free survival (DFS) and overall survival (OS). Patients experiencing these receptor status shifts demonstrate improved outcomes compared to those without changes.
Area Of Science
- Oncology
- Molecular Biology
- Clinical Pathology
Background
- Estrogen receptor (ER), progesterone receptor (PR), and HER2 assessments are standard for invasive breast carcinoma (IBC) before neoadjuvant chemotherapy (NAC).
- Routine post-NAC assessment of these biomarkers in residual tumors is not consistently performed.
- Understanding receptor expression changes post-NAC is crucial for residual disease management.
Purpose Of The Study
- To investigate the alterations in ER, PR, and HER2 expression in pre- and post-NAC biopsies of IBC with residual tumors.
- To evaluate the impact of these receptor expression changes on disease-free survival (DFS) and overall survival (OS).
Main Methods
- A cohort study, encompassing both prospective and retrospective elements, was conducted.
- 174 patients with newly diagnosed IBC, who underwent surgery post-NAC with available pre-NAC biopsies and residual tumors, were enrolled.
- Patients were followed up until July 2022 to assess disease outcomes.
Main Results
- Significant shifts in receptor status were observed: 44% of ER+ cases became ER-, 27% of PR+ cases became PR-, and 36% of HER2+ cases became HER2-.
- Cases exhibiting a change from positive to negative ER and HER2 status showed statistically significant improvements in DFS and OS.
- A minority of cases maintained their positive receptor status, while most ER- and PR- cases remained negative.
Conclusions
- Receptor status (ER, PR, HER2) frequently changes in invasive breast carcinoma patients with residual tumors after NAC.
- Patients experiencing a shift in receptor status post-NAC, particularly from positive to negative, exhibit superior overall survival and disease-free survival.
- These findings underscore the importance of reassessing receptor status in residual breast cancer post-NAC to predict patient outcomes.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...